fatslob-:O said:
It was a $10B+ investment along with the fact that there are now less suitable patients than before because less people get infected with Hepatitis C since a cure is available so it is reasonable why Gilead would charge the drug relatively high prices but when you compare the other available alternative which is paying half a million dollars for a liver transplant with the possibility of a transplant rejection, Sovaldi seemed like a steal by comparison ... I'm surprised why Gilead didn't charge as much as 400K for the entire treatment cause it still would've been a pretty good deal since it was undercutting the next best thing by about 100K which was a transplant operation and the other upside was not having to deal with a graft vs host disease ... Besides, pricing was only a temporary setback for a huge leap forward for the rest of humanity ... |
Considering the number of people in the US with Chronic HCV is estimated to be 3,5 million, that investment would pay for itself within a few years with those prices, so it´s obvious that the prices are set to maximize profit. That is the correct way for a company to go about it, but it is rather an argument for the government to do the research instead.
